April 01, 2025

FDA Approves Freeze-Dried Jynneos Vaccine

Bavarian Nordic’s freeze-dried Jynneos vaccine offers logistical advantages over the liquid-frozen version, supporting long-term U.S. stockpiling and public health preparedness.

Conexiant

April 01, 2025

Medical Oddities: Shrinking Brains, Failing Hearts?

Brains shrink, bots soothe, tea disappoints, and love gets the hormonal spotlight it deserves this week.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 31, 2025

Tobacco Control May Have Prevented Millions of Premature Lung Cancer Deaths in United States

Investigators have examined how tobacco control–driven reductions in smoking prevalence may have helped avert lung cancer–related deaths between 1970 and 2022 in the United States.

The ASCO Post

March 28, 2025

Night Owls Lose Most Sleep to Screens

New study links nightly screen use to later bedtimes, lower sleep quality, and nearly an hour of lost rest each week

Conexiant

March 27, 2025

Medical Oddities: Metabolism’s Secret Sugar-Burning Switch

Science served weird this week: sleepy seniors, sneaky genes, and memory-hacking babies.

Conexiant

March 27, 2025

Trauma Patients Face Lasting Mental Health Risks

Among 26,958 trauma patients without prior psychiatric diagnoses, 11.3% developed a new mental health condition, which was associated with elevated risks of readmission, suicide, and all-cause mortality.

Conexiant

March 27, 2025

Study Finds Significant Increases in Prevalence, Severity of Astigmatism

Prolonged digital device use and reduced outdoor exposure following the COVID-19 pandemic may have contributed to the refractive changes.

Conexiant

March 26, 2025

HER2-Selective TKI in Advanced Solid Tumors with HER2 Alterations

In a phase Ia/Ib study (Beamion LUNG-1) reported in the Journal of Clinical Oncology, Heymach et al evaluated the safety profile and activity of zongertinib in patients with HER2-altered solid tumors....

The ASCO Post